Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 tm2623143d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reduction
EX-99.1 2 tm2623143d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations Announced ulcerative colitis (UC) as the initial disease indication for TTI-109 and will host a KOL webinar on the clinical potential of TTI-109 in UC on August 19, 2026, at 11:00 a.m. ET HOUSTON, TX – August 14, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its financial and operating results for the second quarter ended Ju...
Source
Exhibit EX-99.1
0001104659-26-096417
Filed August 14, 2026 at 11:05 AM UTC. The figures above are from the audited statements, not from this release.